Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland. Founded in 2004 as a spin-off from the University of Zürich, the company specializes in developing DARPin therapeutics, a unique class of small proteins designed to address unmet medical needs in oncology, immuno-oncology, ophthalmology, and infectious diseases. The company's core offering is its DARPin platform, which creates multi-specific and highly stable protein therapeutics. These proteins can target multiple pathways simultaneously, making them suitable for complex diseases. Molecular Partners has two DARPin molecules in clinical development and a broad preclinical pipeline targeting various conditions. The company collaborates with industry leaders like Allergan and Amgen to advance its therapeutic candidates, emphasizing partnerships with pharmaceutical companies, clinical research organizations, and academic institutions. Molecular Partners is committed to transforming lives through innovative therapies, focusing on collaboration and patient-centric innovation.
Work at Molecular Partners in HR or recruiting? Claim this page
Headcount trend
Molecular Partners went from 3 employees in Jul 2023 to 3 in Jun 2025.
Headcount data through Jun 2025
Org structure
Headcount by department
Peer reviews
Worked with someone at Molecular Partners?
Anonymous peer reviews on OffTheRecord
Similar companies
Molecular Partners FAQ
How many employees does Molecular Partners have?
Molecular Partners has about 3 employees, unchanged over the 3 months to Jun 2025.
What is Molecular Partners's revenue per employee?
Molecular Partners makes about $842K in revenue per employee, based on $2.52M annual revenue and 3 employees.
Is Molecular Partners a public company?
Yes. Molecular Partners is publicly traded under the ticker MOLN on NASDAQ.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.